On Friday, Shares of Array Biopharma Inc (NASDAQ:ARRY), lost -3.14% to $4.93.
Array BioPharma, will hold a conference call to discuss preliminary results from two melanoma trials and a colorectal cancer trial on Monday, September 28, 2015. Ron Squarer, Chief Executive Officer, and Victor Sandor, M.D., Chief Medical Officer, will lead the call.
The trials comprise a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2), a Phase 1b/2 combination trial of binimetinib and a CDK4/6 inhibitor in NRAS-mutant melanoma patients and a Phase 2 combination trial of encorafenib and an EGFR inhibitor with or without the addition of a PI3K inhibitor in patients with BRAF-mutant colorectal cancer. Data from these trials will be presented at the European Society of Medical Oncology’s (ESMO) annual European Cancer Conference (ECC) or were presented at the 2015 ESMO World Congress of Gastrointestinal Cancer.
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company’s drugs in Phase III clinical trials comprise Binimetinib and Encorafenib for the treatment of cancer.
Shares of People’s United Financial, Inc. (NASDAQ:PBCT), inclined 0.84% to $15.68, during its last trading session.
People’s United Financial, Inc. (PBCT) declared recently it will release its third quarter financial results on Thursday, October 15 at about 4 p.m. Eastern Time. The company will host a conference call the same day at 5:00 p.m. to discuss its third quarter 2015 earnings declarement.
People’s United Financial, Inc. operates as the bank holding company for People’s United Bank that provides commercial banking, retail banking, and wealth administration services to individual, corporate, and municipal customers.
At the end of Friday’s trade, Shares of B/E Aerospace Inc (NASDAQ:BEAV), gained 1.15% to $44.80.
B/E Aerospace, declared that it anticipates to recognize charges during the third quarter associated with its cost reduction program. The charges reflect costs associated with facilities consolidation, product rationalization, workforce reductions and program discontinuance. The Company plans to close several facilities, consolidate certain product lines and reduce headcount by about 450 employees. Total after-tax charges for the associated activities are predictable to be about $30 million.
“These initiatives are predictable to reduce costs and improve efficiencies which are necessary due to the slower revenue growth predictable in 2015 and 2016. We expect our initiatives to offset inflationary pressures on wages, occupancy and infrastructure costs and enable us to continue to generate incremental year-over-year margin improvement,” said Amin J. Khoury, Executive Chairman of B/E Aerospace.
B/E Aerospace, Inc. designs, manufactures, sells, and services cabin interior products for commercial aircraft and business jets in the United States and internationally. Its Commercial Aircraft segment offers first class, business class, tourist class, and regional aircraft seats, in addition to spares; oxygen storage, distribution, and delivery systems for commercial and business jet aircraft; coffee makers/water boilers, ovens, and refrigeration equipment; and modular lavatory, wastewater, and galley systems.
Finally, Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), ended its last trade with -4.97% loss, and closed at $149.25.
Alexion Pharmaceuticals, declared that researchers will present new data on the long-term efficacy and tolerability of Strensiq (asfotase alfa) in children with hypophosphatasia (HPP) who were treated for up to five years, in addition to new data comparing the functional mobility of children with HPP treated with Strensiq contrast to untreated historical control patients. Researchers will also present new data on the dosing for Strensiq in patients with HPP and the use of the Radiographic Global Impression of Change (RGI-C) scale for assessing skeletal manifestations of HPP in infants and children, together with a case literature review of HPP manifestations in adults with pediatric-onset HPP. The data will be presented at the 2015 American Society for Bone and Mineral Research (ASBMR) Annual Meeting being held October 9-12, 2015, in Seattle.
HPP is a genetic and progressive metabolic disease in which patients experience devastating effects on multiple systems of the body, leading to debilitating or life-threatening complications. It is an ultra-rare disease, which is defined as a disease that affects fewer than 20 patients per one million in the general population.1 HPP is characterized by defective bone mineralization that can lead to deformity of bones and other skeletal abnormalities, in addition to systemic complications such as profound muscle weakness, seizures, pain, and respiratory failure leading to premature death in infants.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
